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Abstract
Pharmacogenomics and personalized medicine incorporate genetic factors, historical data, and 
environmental exposures to predict individual variation in response to medications. The study of 
pharmacology and pharmacogenomics is challenging in obstetrics, and knowledge lags behind 
other disciplines of medicine. However, some preliminary data suggest that some of the inter-
individual variation seen in response to medications given for the prevention (progesterone) and 
treatment (nifedipine, terbutaline, others) of preterm labor may be due to pharmacogenomic 
effects. A comprehensive approach, integrating clinical data, environmental factors including 
concomitant medications, and genotype to optimize prevention and treatment strategies for 
preterm birth, is urgently needed.
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Personalized Medicine and Pharmacogenomics – Introduction
Pharmacogenomics is the application of genomic and molecular data in order to better target 
the delivery of healthcare, facilitate the discovery and clinical testing of new products, 
and/or help determine an individual’s predisposition to a particular disease or condition.(1) 
Importantly, it helps to correlate genetic data with a drug’s efficacy or toxicity. Broadly 
defined, personalized medicine includes pharmacogenomics, and is a rapidly expanding area 
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of medicine. Personalized medicine is multifaceted, and includes genetic factors, historical 
factors (e.g., family history, personal medical, obstetric history), and environmental factors 
(e.g. concurrent medication use, exposure to tobacco smoke), and synthesizes this 
information with the overall goal of individualizing medical care and treatment to optimize 
outcomes. The goal of personalized medicine is to provide the ‘right dose of the right drug 
for the right patient at the right time.’(1) The number of identified associations between 
genetic factors and disease has recently increased at an exponential level due to 
improvements in genetic technology, helping to accelerate the development of genetic 
factors as biomarkers.
It is important to recognize that personalized medicine and pharmacogenomics are not just 
about finding the ‘right medication’ to treat a condition. Adverse drug reactions are a 
leading cause of morbidity and mortality in developed countries among both children and 
adults. It has been estimated that between 0.6% and 17.7% of hospitalized patients 
experience a serious adverse drug reaction.(2, 3) This places a substantial burden on 
healthcare resources, estimated at nearly 20% additional increase in cost of care and an 
increase in average length of hospital stay of 8.3%.(4) Application of pharmacogenomics 
knowledge has the potential to individualize medications and doses, and may minimize 
adverse effects.
Traditionally, medication prescribing has been at a diagnosis level. A group of patients with 
a common diagnosis are administered a standard medication at a standard dose. This 
medication and dose will work for the majority of patients; however, the dose may be too 
high for some, causing adverse side effects, too low for others, who may not achieve the 
desired efficacy, and may be harmful or ineffective all together (regardless of dose) for a 
smaller subset of individuals. In contrast, in an era of personalized medicine prescribing, the 
same group of individuals with a common diagnosis would first undergo DNA or other 
testing prior to medication prescribing; this information, together with history and 
environmental data, would aid the prescribing provider in determining the optimal dose for 
that individual. Additionally, the group of patients unlikely to respond to that medication 
could be identified and could be given a different medication, minimizing side effects and 
toxicity, while improving outcomes (Figures 1a and 1b). This concept, sometimes also 
referred to as ‘stratified medicine,’ has the potential to improve not only individual 
outcomes, but have also have positive societal economic impacts.(5, 6)
Current Real World Applications of Pharmacogenomics in Medicine
Pharmacogenomic information is currently provided by the FDA for over 130 drugs; this list 
is continuously updated online.(7) Many of the medications with pharmacogenomic labeling 
are commonly prescribed; it has been estimated that 25% of all outpatient prescriptions 
includes one of these medications.(8) Currently, more than 50 genes have been implicated as 
genomic biomarkers; most commonly, these biomarkers pertain to polymorphisms in 
cytochrome P450 (CYP) enzyme metabolism. Polymorphisms in CYP enzymes are 
relatively common. For example, CYP2D6 is estimated to metabolize approximately 25% of 
drugs, and is known to be very polymorphic. Over 70 alleles have been identified in this 
gene, and as a result, CYP2D6 activity ranges widely, even within populations.(9, 10) Up to 
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8% of European Americans will be identified as ‘poor metabolizers.’ Given that this is only 
one hepatic enzyme involved with metabolism, this bespeaks the importance of developing 
companion diagnostic tests to accompany pharmaceuticals.
Although arguably the translation of pharmacogenetic research findings into clinical practice 
has been slow, the best pharmacogenetic evidence exists in disease areas outside of womens 
health, including asthma, anti-coagulation, antibiotics, and oncology. Examples of drugs 
with pharmacogenomics information include warfarin, cyclosporine, and clopidogrel. 
Another example is the drug ivacaftor, which was approved by the FDA as a ‘targeted’ 
therapy for individuals with cystic fibrosis due to a specific genetic mutation, and is 
somewhat revolutionary in the field because it targets the underlying cause of cystic fibrosis 
rather than the symptoms of the disease. In the field of obstetrics, this would be the 
equivalent of targeting the underlying etiology of short cervix with a medication, rather than 
waiting for the cervix to shorten and then treating it with progesterone. Arguably, this would 
be more challenging in the situation of short cervix (or other underlying etiologies of 
preterm birth), which is likely to be a polygenic condition.
Another example of current real world use of pharmacogenomics can be seen in the online 
pharmacogenetic clinical calculator, developed to assist physicians with dosing warfarin 
(www.warfarindosing.org). Traditionally, warfarin dosing for anticoagulation has been 
fraught with inter-individual variability, and has resulted in prolonged hospitalizations for 
some individuals (while awaiting a therapeutic INR) and potential serious adverse effects for 
others, who become supra-therapeutic on standard dosing regimens. The online warfarin 
calculator includes input fields for demographic factors (age, sex, ethnicity), environmental 
factors (smoking, liver disease, concomitant medications), laboratory values (baseline INR, 
target INR), and genetic data (genotype for several single nucleotide polymorphisms SNPS 
in drug metabolizing enzymes). The output provides patient specific estimated warfarin 
dosing information. This tool is freely available and is just one example of how 
pharmacogenomics information can be directly applied to improve patient care.
Challenges Involved with Pharmacogenomics Applications in Obstetrics
Given the challenges involved with pharmacologic research during pregnancy, 
pharmacogenetic studies among pregnant women are limited. There are pharmacogenetic 
data, although many preliminary and on non-pregnant subjects, on several medications 
commonly used among pregnant women, including nifedipine, omeprazole, and many 
selective serotonin reuptake inhibitors among others (Table 1).(7) Unfortunately, obstetric 
providers are often forced to extrapolate knowledge regarding prescribing of many 
medications from the non-pregnant population when caring for gravidas in need of 
treatment. The same holds true for the application of pharmacogenomics; again, clinicians 
and researchers are left to deduce information based on studies among non-pregnant 
individuals. Although current literature in the study of pharmacogenomics during pregnancy 
(for a spectrum of medications and indications) is limited, researchers have suggested a role 
in of maternal and/or fetal genotype and response to medications for epilepsy and 
depression/anxiety.(11–13) Others have suggested that genotype should also be considered 
when studying drug-induced teratogenicity.(14, 15)
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Variability in patient response to medications is very common in general, but pregnancy 
further accentuates these inter-individual differences. This can be summarized by the 
changes in physiology that occur during pregnancy that alter the absorption, distribution, 
metabolism, and elimination of drugs. When any of these properties are altered, efficacy can 
also be altered. During pregnancy, there are 2 patients to consider, and the fetus has a 
different genotype than the mother. This is important to remember, particularly since 
medications are commonly prescribed to a pregnant woman with the intention of preventing 
an adverse outcome in her fetus or fetuses. The placental unit needs to be accounted for; 
some medications easily cross the placenta, whereas others do not. Physiology changes at 
least every trimester, and pharmacodynamics and pharmacokinetics are also altered, due to 
changes in volume of distribution and protein binding, among other factors.(16–18) For 
example, the half-life of labetalol, a commonly used anti-hypertensive during pregnancy, 
decreases significantly during pregnancy due to altered pharmacokinetics during pregnancy. 
(19) The exact effects of some of these physiologic changes are hard to quantify on an 
individual drug basis, as studies are limited, and many are performed in only the third 
trimester when the fetal risk is thought to be the lowest. A thorough review of the 
pharmacokinetic and pharmacodynamics changes that occur during pregnancy is beyond the 
scope of this review, but an overview of major changes is summarized in Table 2.
Lastly, many disease processes that are studied during pregnancy should be regarded as 
‘final common pathways.’ Because many pregnancy complications may result from different 
initial etiologic processes, a ‘one size fits all’ treatment approach that is commonly 
employed for conditions including pre-eclampsia, preterm birth (PTB), etc. may be 
ineffective for most individuals. Furthermore, neonatal outcomes are often used as a 
surrogate for long term outcomes, providing additional challenges in the study of 
therapeutics during pregnancy.(20)
Current Pharmacogenomics Knowledge Related to Preterm Birth 
Prevention and Treatment
Preterm birth (PTB) remains the leading cause of neonatal morbidity and mortality among 
non-anomalous infants in the developed world. A prior PTB is the greatest risk factor for 
recurrence, and thus, women with a history of a PTB have been the focus of many 
intervention trials during pregnancy.(21, 22) In 2003, Meis and colleagues published results 
from a double blind randomized controlled trial demonstrating that prophylaxis with 250mg 
of weekly intramuscular 17-alpha hydroxyprogesterone caproate (17-OHPC) beginning at 
16–20 weeks gestation reduces the recurrence risk of PTB among high risk women. The 
original Meis study demonstrated a significant reduction in recurrent PTB with 17-OHPC, 
with a RR of 0.66 (95% CI 0.54–0.81).(23) Despite this significant reduction, 17-OHPC 
does not help everyone. Additional studies have shown that 17-OHPC (regardless of dose or 
dosing regimen) is ineffective for other groups of women at high risk for PTB, including 
those carrying twins or triplets and women with an asymptomatic short cervix in the mid-
trimester.(24–26) The reasons for this variation in response are unknown. It is possible that 
there is a critical 17-OHPC concentration (which may vary among individuals) required to 
achieve ‘response.’ This theory is supported by a pharmacokinetics study done by Caritis 
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and colleagues. They examined 17-OHPC plasma concentrations from 315 women at 25–28 
weeks gestation, and grouped results into quartiles within their patient population. Women 
with 17-OHPC concentrations in the lowest quartile were significantly more likely to have a 
recurrent PTB than those who had a 17-OHPC plasma concentration in the upper 3 quartiles 
(46% vs. 29%, p=0.03); they also demonstrated that those women in the second to fourth 
quartiles had a 50% reduction in the hazard of delivering preterm (Hazard ratio, 0.48, 
95%CI 0.31–0.75, p=0.001) compared to those with plasma 17-OHPC concentrations in the 
first quartile.(27) Additionally, the lowest PTB rates were seen when median 17-OHPC 
concentrations exceeded 6.4 ng/mL.
Two specific pharmacogenomics studies have been performed to examine the relationship 
between genotype and response to 17-OHPC. The first was a candidate gene study, 
examining 20 single nucleotide polymorphisms (SNPs) in the progesterone receptor gene. 
Individuals were defined as ‘responding’ to 17-OHPC if they delivered at term with 17-
OHPC. The majority of findings in this study were consistent with the expectation that 
decreased rates of SPTB would be found across genotypes among individuals who received 
17-OHPC, consistent with findings from the initial Meis study. For example, self-identified 
African-Americans with the AA genotype at rs471767 who received placebo had an OR of 
PTB of 1.0; those who received 17-OHPC had a reduced odds of PTB (0.20); in contrast, 
those with either the AG or GG genotype for this SNP had similar rates of PTB with 17-
OHPC. However, some surprising findings were noted; women with certain genotypes 
might have an increased risk of PTB when treated with 17-OHPC compared to their 
‘background’ rate of prematurity. An example of this is Caucasians and Hispanics at 
rs503362; those with the GG genotype had an increased odds of PTB <32 weeks gestation 
with 17-OHPC, while those with the CG or CC genotype at this SNP who received 17-
OHPC had a significant reduction in PTB compared to those receiving placebo.(28)
This study was a reasonable initial investigation, and suggested a possible interaction 
between maternal genotype, 17-OHPC, and response to therapy, but had several limitations. 
First, the study was limited by the examination of only the progesterone receptor gene. A 
single gene etiology is very unlikely for this complex phenotype incorporating 
pharmacogenomics. A broader approach, in an era of improved genetic technology, is to 
employ next generation sequencing. Sequencing provides all genetic information and is not 
subject to investigator bias or preconceived ideas regarding causative variants. Second, the 
study was limited by the definition of progesterone ‘responder.’ Traditionally, responders to 
progesterone are those individuals who are administered 17-OHPC and deliver at term. This 
may misclassify many women as non-responders who gain significant gestational age with 
17-OHPC but do not reach 37 weeks gestation. Even small gains in gestational age may 
have large impacts on neonatal and childhood morbidity and mortality. PTB tends to recur at 
similar gestational ages; e.g. a woman with a prior PTB at 24 weeks who experiences a 
recurrent PTB is likely to experience this recurrence around 24 weeks gestation. Thus, a 
woman with a prior 24 week delivery who receives 17-OHPC and reaches 34 weeks 
gestation would not be considered a 17-OHPC responder using the traditional definition of 
responder, since she did not reach term, but the outcomes for her 34 week baby are expected 
to be significantly improved compared to her first, earlier delivery. Given this, a ‘new’ 
definition of 17-OHPC responder was created. Those who delivered at least 3 weeks later 
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than the gestational age of the earliest prior PTB without 17-OHPC were considered 
‘responders’ and those who delivered earlier with 17-OHPC than without it or <3 weeks 
later with 17-OHPC were considered non-responders.
Next, using both a broader genetic approach, and the refined definition of progesterone 
responder, another study was performed on a different cohort of women. This study 
recruited women from a prematurity prevention clinic in Salt Lake City, UT. Maternal 
samples underwent whole exome sequencing. Data were analyzed at the gene level using the 
Variant Annotation, Analysis and Search Tool (VAAST, Salt Lake City, UT).(29, 30) 
VAAST prioritized those genes with different allele frequencies between responders and 
non-responders; the top genes were then examined in a pathway analysis. Statistically 
significant over-representation of several biologic processes and molecular functions was 
found. For example, genes in the nitric oxide signal transduction pathway were found to be 
over-represented among non-responders compared to responders.(31) Nitric oxide is known 
to be a potent uterine smooth muscle relaxant, and may work synergistically with 
progesterone to inhibit uterine contractility.(32, 33) Small randomized controlled trials of 
unselected women examining the role of nitroglycerin (typically administered in patch form, 
converted to nitric oxide) for preterm birth tocolysis have produced mixed results, and a 
recent metaanalysis concluded there is no apparent benefit for this indication.(34) Whether 
nitroglycerin may be an appropriate adjunct to 17-OHPC in some high risk women remains 
unknown and is an area for future research.
Pharmacogenomics of Preterm Birth Treatment
Nifedipine
Nifedipine is a calcium channel blocker commonly used as a tocolytic. It has a favorable 
efficacy and safety profile overall. It is metabolized by the polymorphic CYP3A family of 
metabolic enzymes in the liver. One small study of 14 women receiving nifedipine tocolysis 
genotyped participants for CYP3A5, and analyzed nifedipine concentration over time. These 
investigators found that CYP3A5 genotype correlated with clearance of nifedipine; those 
individuals who were CYP3A5 high expressers metabolized nifedipine more quickly and 
had lower serum levels of nifedipine across the study period.(35) In another pilot study of 20 
pregnant women, Haas and colleagues examined 20 pregnant women receiving nifedipine 
for preterm labor. CYP3A5 genotype was found to correlate with nifedipine levels. Those 
women who had the high expresser genotype were again found to have lower nifedipine 
levels. Importantly, this study also showed that these individuals who were CYP3A5 high 
expressers had less improvement in contraction frequency at several time points – after the 
loading dose, at the steady state, and in the first hour after the study dose.(36)
Beta-2 adrenergic receptor agonists
Beta-2 adrenergic receptor agonists are commonly used tocolytics in Europe and Canada. 
They work through binding the beta-2 adrenergic receptor and causing smooth muscle 
relaxation. There is known genetic variability within the beta-2 adrenergic receptor. An 
arginine to glycine substitution at codon 16 (Arg16Gly) has been shown to increase receptor 
desensitization in response to agonist exposure. A substitution of glutamate for glutamine at 
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codon 27 (Gln27Glu) decreased down regulation of the receptor. There have been several 
candidate gene studies in different populations which have found a relationship between 
polymorphisms in the beta-2 adrenergic receptor and PTB. For example, Gibson and 
colleagues reported that a variant of the beta-2 adrenergic receptor gene (ADRB2 Q27E) is 
more common among a cohort of 147 children born preterm who did not eventually develop 
cerebral palsy.(37) Other studies have also supported the possible relationship between 
beta-2 adrenergic receptor polymorphisms and PTB.(38–40)
Adding in the element of pharmacogenomics to response to beta-2 adrenergic agonists thus 
seemed a logical ‘next step,’ but such studies remain small and limited. In 2005, Landau and 
colleagues examined 60 women with preterm labor, and genotyped them for the beta-2 
adrenergic receptor. Women with the AA genotype at codon 16 were noted to have a 
significant prolongation in gestation, and the authors reported that tocolysis was 100% 
successful in delaying delivery for 48 hours (n=10, p=0.069). Among the remaining 50 
women with either the AG or GG genotype at codon 16, only 37 had delivery delayed by 
more than 48 hours with beta-2 agonist tocolysis. Gestation was noted to be significantly 
prolonged among those homozygote for the minor allele, 69 days vs. 58 days, p=0.04); 
neonatal outcomes were also improved. The authors concluded that women with an AA 
genotype may have improved response to beta-2 agnoist tocolysis.(41) An additional 
pharmacogenetic study of ritrodine therapy demonstrated that individuals homozygous for 
the minor allele in rs1042713 or who carried at least one copy of the minor allele for 
rs1042719 had a significantly shorter admission to delivery interval compared to those with 
the more common wild-type genotypes.(42)
Indomethacin and Magnesium Sulfate
Indomethacin is another commonly used tocolytic. It is metabolized by the polymorphic 
CYP2C9 and CYP2C19 enzymes in the liver.(43) Magnesium sulfate is also commonly used 
for tocolysis and among mothers at risk of PTB for the purposes of fetal neuroprotection.
(44) Magnesium sulfate is renally excreted, and levels are affected by volume of distribution 
and glomerular filtration rate.(45) It is possible that genotype may affect indomethacin 
and/or magnesium sulfate concentration and efficacy, but this is speculation only; no 
pharmacogenomics data are currently available.
Betamethasone
In a study of 109 women and their 117 neonates delivering at a mean 32.2 weeks gestation, 
72% due to preterm premature rupture of membranes or PTL, Haas and colleagues 
examined 73 maternal and fetal SNPs in glucocorticoid pathways. After controlling for 
confounders, they found that maternal and fetal genetic variants in several SNPs, including 
CYP3A5 and CYP3A7*1E to be associated with variation in neonatal respiratory outcomes, 
including respiratory distress syndrome, need for surfactant, and ventilator support.(46) 
Thus, these authors concluded that genetic variation in key betamethasone pathway genes 
may be associated with the severity of respiratory morbidity.
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Conclusions and Future Directions
Preliminary data suggest that genotype may influence response to commonly used 
therapeutics administered for recurrent PTB prevention and treatment. Studies to date are 
small and limited, but evolving. Unfortunately, pharmacogenomics is not yet ready for 
clinical implementation in obstetrics. Future studies should focus on confirming the results 
of the preliminary studies presented here, expand to examine the influence of fetal genotype, 
and also incorporate functional data and protein expression information. A comprehensive 
approach to personalized medicine, integrating clinical data, environmental factors including 
concomitant medications, and genotype to optimize prevention and treatment strategies for 
PTB, is urgently needed. Only then will we be able to screen low-risk women and impact 
primary PTB prevention.
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Figure 1. 
a. Schematic of traditional medication prescribing
b. Schematic of medication prescribing in an era of personalized medicine.
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Table 1
Pharmacogenetic information in the FDA label of medications commonly prescribed to pregnant women.
Drug name Indication for
use during
pregnancy
Gene* Pharmacogenomic Information in FDA Label
Glyburide Diabetes mellitus G6PD Precautions: Hemolytic anemia related to G6PD deficiency
Omeprazole, Lansoprazole Gastroesophageal reflux disease CYP2C19 Drug interactions: CYP2C19 poor metabolizers should avoid 
concomitant use of clopidogrel
Metoclopramide Nausea G6PD Precautions: individuals who are NADH cytochrome b5 
reductase deficient are at risk of methemoglobinemia
Nitrofurantoin Urinary tract infection G6PD Warnings: individuals with G6PD deficiency are at risk of 
hemolytic anemia
Fluoxetine Depression, anxiety CYP2D6 Warnings, Precautions: CYP2D6 poor metabolizers may have 
higher drug levels; concomitant administration with other drugs 
metabolized by CYP2D6 may exacerbate this effect
Paroxetine Depression, anxiety CYP2D6 Warnings, Precautions: CYP2D6 poor metabolizers may have 
higher drug levels; concomitant administration with other drugs 
metabolized by CYP2D6 may exacerbate this effect
Metoprolol Hypertension CYP2D6 Warnings, Precautions: drugs that inhibit CYP2D6 such as 
quinidine, fluoxetine, paroxetine are likely to increase 
metoprolol concentration and decrease the cardioselectivity of 
metoprolol; this is exacerbated in subjects with CYP2D6 
extensive metabolizer phenotypes
Codeine Analgesia CYP2D6 Black box warnings: respiratory depression and death have 
occurred in children who received codeine who were CYP2D6 
ultra-rapid metabolizers. Deaths have also occurred in nursing 
infants who were exposed to high levels of morphine 
(metabolite of codeine) in breast milk because their mothers 
were ultra-rapid metabolizers of codeine
*Standard nomenclature as per the Human Genome Organization symbol
Source: US Food and Drug Administration: Table of Pharmacognomic Biomarkers in Drug Labeling. (Accessed 5/5/2015, at http://www.fda.gov/
Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm.)
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Table 2
Summary of physiologic and metabolic changes potentially affecting pharmacotherapy during pregnancy.
Change Impact on Pharmacotherapy
Slower gastric emptying, reduced intestinal 
motility
- May impact drug absorption
Increase in gastric pH - May impact drug absorption
Increased glomerular filtration rate (40–
80%)
- Enhanced renal drug elimination
- Decreased steady-state concentrations of many drugs
Increase in total volume of distribution - Altered drug distribution
- Decreased peak serum concentration of many drugs
Hypoalbuminemia - Decreased protein binding, and increased free drug fraction
Change in metabolic enzyme activity - Altered drug metabolism:
○ CYP1A2, CYP2C19 activity/expression is decreased
○ CYP2A6, CYP2C9, CYP2D6, CYP3A, uridine glucuronyltransferase activity/
expression is increased
Presence of placenta - Additional metabolism and transport of some drugs
BJOG. Author manuscript; available in PMC 2017 February 01.
